Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's Disease
Go back to Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's Disease| Axion Spatial Imaging Inc (NASDAQ: AXON) | Delayed: 435.24 +25.21 (6.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $410.03 | 52 Week High | $21.30 | |||
| Open | $414.44 | 52 Week Low | $8.86 | |||
| Day High | $441.11 | P/E | N/A | |||
| Day Low | $414.44 | EPS | $0.00 | |||
| Volume | 760,443 | |||||
